Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] CUVITRU is Takeda’s First Subcutaneous Immunoglobulin Plasma Therapy in Japan,
